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In the european Union, the use of recombinant bovine somatotropin (rbst) in dairy cattle is forbidden. 
Monitoring rbst (ab)use by its direct detection in animal matrices still remains a challenging task. New 
monitoring methods based on indirect detection of the substance are necessary. A new transcriptomic 
system based on the use of high-throughput real-time pCR in combination with somatic cells was 
developed to control rbst administration in dairy animals. A total of nine cows, separated into control 
and rbST-treated groups, were included in the study. A subcutaneous injection containing 500 mg 
of rbST was administered to the treated group every 14 days, up to a total of 12 doses. Milk somatic 
cells (MSCs) were sampled from each animal at different time points throughout 8 months of study. 
It was possible to obtain the transcriptomic profile of 18 genes in MSCs of rbST-treated and control 
groups, and using univariate and multivariate statistical analysis control and treated animals were 
discriminated. The transcription of CCND1, IGF-1R, TNF and IL-1β genes resulted strongly influenced 
by rbst treatment. the combination of MsCs, transcriptomic tools and statistical analysis has allowed 
the selection of four genes as potential biomarkers that could be used in a transcriptomic panel for 
monitoring rbst administration in cows.
Bovine somatotropin (bST) is a peptide hormone synthesized by cows’ pituitary glands. It acts by binding to 
membrane-bound receptors located in different tissues such as liver, bone or mammary glands. A pioneer study 
by Asimov and Krouze1 in the 1930s discovered that injections of pituitary extract induced an increase in milk 
yield of dairy cattle, and research carried out by Folley and Young found that these galactopoietic effects were due 
to somatotropin2,3. The development of DNA recombinant technology made the industrial production of recom-
binant bovine somatotropin (rbST) economically practicable4. This production system opened the door for the 
commercial use of rbST in dairy cows to increase milk yield. In 1993, the Food and Drug Administration of the 
United States (FDA Agency) approved for the first time the use of rbST in dairy cows. Although possible rbST res-
idues contained in milk from treated animals should be destroyed in the human digestive system, there are some 
non-clarified concerns about its safety for consumers. As a matter of fact, it has been reported that rbST treatment 
may cause an increase on insulin-like growth factor (IGF-1) in milk, in comparison to milk from non-treated 
dairy cattle5–7. As IGF-1 levels are not altered by pasteurization of milk8, the hypothesis of IFG-1 reaching the 
consumer seems plausible and biologically feasible9.
The use of rbST in cattle is legal in some countries such as the United States, Mexico and Brazil. However, 
in 1999, the European Union decided to ban the use of rbST invoking animal welfare reasons and the impact of 
European milk policy and consumers fears10. The banning of rbST resulted in the need for developing analytical 
methods to detect its fraudulent use. As a relatively recent example, in 2013 the Spanish authorities detected that 
many farmers had been administering rbST to their cows using commercial injections of rbST (Lactotropin® 
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and Boostin®) from Mexico illegally introduced into Spain. In a recent report, Sterk11 established the use of 
rbST as a current challenge to European residue control plans. In this context, analytical methods such as liquid 
chromatography coupled to mass spectrometry, based on the direct detection of the banned substance, are the 
first option to detect its use12. In this context, some research groups have successfully developed some methods 
based in the use of liquid chromatography coupled to mass spectrometry to detect rbST in plasma, serum13–16 
and milk17. However, some commercially available forms rbST have the same amino acid composition as natural 
bST, rendering practically impossible their differentiation18. Therefore, it is also of great importance to develop 
indirect methods that allow detection of rbST administration in cattle. In this sense, some research works have 
developed ELISA methods to detect rbST antibodies in serum and milk19,20. Other studies have developed meth-
ods based in the determination of multiple protein biomarkers to detect the use of rbST in dairy cattle5,21. Even, 
the clinical biochemical and hormonal profiling in plasma was evaluated as a potential tool to predict the use of 
rbST in cattle22.
In recent years, transcriptomics technology has experienced a boom due to the development of RNA sequenc-
ing (RNA-seq), microarrays and high-throughput real-time PCR systems. While RNA-seq and microarrays per-
form massive measurements of the transcriptome in a reduced number of samples, high-throughput real-time 
PCR enables the analysis of various genes at the same time in a large number of samples23. Besides, real-time 
PCR is considered the gold standard for quantification purposes, permitting identification of small differences 
between samples with better precision than RNA-seq and microarrays. Recently, some research groups have used 
transcriptomics as a tool to detect the use of growth promoters in beef cattle24,25. However, these studies focused 
on the use of target tissues such as liver or muscle obtained after slaughtering. Other studies have been focused 
on the use of blood cells26. Although blood samples enable transcriptomic controls in vivo, they require direct 
contact with animals and invasive sampling procedures. In the specific case of rbST, it is essential to monitor its 
misuse during the period of lactation, before milk reaches the market, and therefore the collection of samples 
after slaughtering animals is not a real option in terms of food safety. All this means that target samples must 
be easy to collect, the method of sample collection must cause minimal or no pain to the animal, and it has to 
be economically viable. One of the main target tissues of rbST in dairy cattle is the mammary gland, where this 
peptide hormone exerts an important galactopoietic effect. Due to this direct relationship, recent studies have 
used post-mortem mammary tissue to evaluate the effect of rbST on its transcriptional profile27. However, as 
mentioned before, it is important to detect the use of this substance during lactation to avoid the entry of milk 
produced using rbST into the market. At this point, milk somatic cells appear as a good alternative to carry out 
in vivo transcriptomic assays to detect the use of rbST. A comparative study, in which five different RNA sources 
were evaluated to examine the lactating bovine mammary gland transcriptome, concluded that detecting MSCs 
released into milk during lactation is one of the simplest methods to isolate RNA. Also, the MSC transcriptome 
is representative of mammary gland tissue and can be used as an effective alternative to study mammary gland 
tissue gene expression without the need for a tissue biopsy28. In a practical way, Toral et al.29 demonstrated the 
potential of MSCs from dairy ewes as an alternative to mammary biopsies in performing nutrigenomic studies.
The aim of this study is to evaluate the potential of high-throughput real-time PCR to obtain a gene expression 
profile in MSCs collected from cows treated with rbST. To represent real farm conditions and to differentiate this 
work from the transcriptomic studies carried out until now in relation to rbST, nine cows were housed separately 
in a semi-extensive dairy farm, and a total of 12 injections of Lactotropina® were administered to six of them, 
in two-week intervals. MSCs were collected from six treated cows and three control animals at 36 different time 
points to analyse the expression of selected genes and seek transcriptomic differences between groups. Additional 
control samples from rbST-free farms have been also included.
Material and Methods
Animals and treatments. As described in a previous work carried out by this research group30, nine 
Holstein cows in first or second lactation and in an age range from 1.5 to 4 years were chosen from a herd of 
dairy cows and housed separately at the same farm. Feed was distributed to the cows twice a day, and they had 
ad libitum access to fresh water. Milking was carried out in a herringbone milking parlor in two sessions, at 8:00 
and 18:00 hours. Milk production in volume of each individual animal was recorded every day during eight 
consecutive months (240 days) by using individual milk meters, starting collecting data eighteen days before the 
first rbST dose (pre-dose or conditioning period) and finalizing 1.8 months (54 days) after the last dose of the 
treated group. The nine cows were divided into two groups: control group composed of three cows and rbST-
treated group composed of six cows. The rbST group was treated with 500 mg of rbST (Lactotropina®, Elanco®, 
Eli Lilly, Mexico) subcutaneously every 14 days (the period between a rbST injections and the next administra-
tion is considered a rbST cycle), according to the manufacturer’s recommendations, during a total period of 6 
months. Lactotropina® syringes were kept refrigerated and left to warm to room temperature before use. During 
each treatment, a veterinary surgeon introduced the syringe subcutaneously behind the shoulder after removing 
surface dirt with alcohol and alternating between the cow’s left and right side on consecutive injections. At the 
time of the first dose, rbST animals have been 67 ± 4 days in lactation (lactation peak) and control animals 75 ± 4 
days. A total of 12 rbST doses were administered to the treated group during the study, and milk samples of the 
first milking of the day were collected from both control ant treated animals at different time points during the 
whole experiment (Fig. 1). Between the fifth and sixth rbST treatment, there was a 28-day gap with no rbST dose. 
Also, since the last rbST dose was administered, milk production was recorded by two months. It was made to 
determine the existence of some effect of this lack of dose on gene expression of rbST group in comparison to 
control group. Experimental procedures were performed after evaluation and on approval of the corresponding 
regional authorities (Service of Livestock Farming of the Provincial Government of Lugo, Regional Ministry of 
Rural Affairs, Galicia), in accordance with EU guidelines and national laws on animal experiments, in particular, 
Directive 2010/63/EU on the protection of animals used for scientific purposes, and its transposition into national 
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law. All procedures were performed respecting animal welfare and causing no more pain, suffering, distress or 
lasting harm than the equivalent to that caused by the introduction of a needle in accordance with good veteri-
nary practice.
Milk somatic cell collection. The collection of milk somatic cells (MSCs) was carried out as previously 
described by our research group30. Briefly, a total of two litres of homogenized milk from the morning milking of 
each cow were collected at the milking parlour in sterile bottles (Deltalab, Spain) and immediately transported in 
refrigerated conditions to the laboratory. Before milking, udder was cleaned and first contaminated milk streams 
were dismissed. The remaining milk that was not collected for experimental assays was discarded. A total volume 
of 225 mL of fresh milk was used to collect MSCs for analysis. For this purpose, 50 mL conical centrifuge poly-
propylene tubes were filled with 45 mL of milk and centrifuged at 2,300 RCF for 10 min at 4 °C. The supernatant 
(fat and whey) was discarded, keeping the pellet, and then the tubes were filled again with 45 mL of milk and cen-
trifuged once more. This step was repeated five times for each sample in the same conical plastic tube to concen-
trate the pellet. Then, the milk pellet containing the MSCs was mixed with 1 mL of TRIzol (AmbionTM, Thermo 
Fisher Scientific, Massachusetts, USA), transferred to a 1.5 mL microtube and stored at −20 °C until further use. 
Following the same procedure, a total of three MSCs samples from three different cows belonging to an external 
dairy farm unrelated to the farm where the cows of the study were housed were collected.
total RNA extraction and reverse transcription. As described in a previous work30, total RNA was 
extracted using TRIzol Reagent (AmbionTM, Thermo Fisher Scientific, Massachusetts, USA) according to the 
manufacturer’s protocol. Quantification of the RNA was carried out with a Qubit® RNA BR Assay Kit and a 
Qubit® fluorometer (InvitrogenTM, Thermo Fisher Scientific). The A260/280 ratio of RNA samples was deter-
mined by using BioDrop μLITE (BioDrop, UK). RIN value was determined using the 2100 BioAnalyzer (Agilent 
Technologies, CA, USA). A total of 1 µg of RNA was reverse-transcribed to cDNA using a High-Capacity cDNA 
Reverse Transcription Kit with RNase Inhibitor (Applied BiosystemsTM, Thermo Fisher Scientific) according to 
the manufacturer’s instructions. cDNA samples were stored at −20 °C until further use.
Nanolitre high-throughput qpCR. The expression of 18 genes (Table 1) in MSCs was evaluated by 
real-time PCR. The selection of those genes was mainly based in previous transcriptomic studies of cows treated 
with rbST and anabolic agents26,27,31,32. Of these 18 genes, three were used as endogenous controls to calculate the 
relative expression of the other 15 candidate genes. Gene expression profiling was carried out with a TaqMan® 
OpenArray® system (Applied BiosystemsTM, Thermo Fisher Scientific) as described in a previous work30. This 
is a nanolitre high-throughput real-time PCR platform where 3,072 reactions are performed at the same time 
in the same OpenArray® plate, and the primers and TaqMan® probes are preloaded in the plates by the com-
pany. A plate design of 18 assays in triplicate and 56 samples was chosen. Real-time PCR reactions were per-
formed according to the TaqMan® OpenArray® protocol. Briefly, in a 384-well plate, 1.2 µL of each cDNA sample 
was mixed with 3.8 µL of TaqMan® OpenArray® Real-Time PCR Master Mix (Applied BiosystemsTM, Thermo 
Fisher Scientific). The PCR reaction mixtures were loaded automatically into the OpenArray® plates using an 
OpenArray® AccuFill™ System (Applied BiosystemsTM, Thermo Fisher Scientific). The following real-time PCR 
protocol was used: 40 cycles at 95 °C for 15 s, and 60 °C for 1 min.
Data analysis and statistics. RT-PCR data analysis. As described in a previous work30, the LinRegPCR 
software was used to analyse the raw real-time PCR data33,34 and calculate PCR efficiency. LinRegPCR imports 
Figure 1. Overview of the rbST animal experiment, showing the days of milk sample collection (marked with a 
tube with a blue cap), and the days of animal treatment (days highlighted in bold numbers).
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non-baseline-corrected data and performs a baseline correction on each sample. Then, a window of linearity is 
determined, and linear regression analysis is used to determine the PCR efficiency per sample from the slope of 
the regression line. The mean PCR efficiency of each amplicon tested and the Cq value per sample were used to 
calculate a starting concentration (N0) per sample, expressed in arbitrary fluorescence units. After that, Factor 
Correction qPCR software was used to remove multiplicative between-session variation in experiments35. A ses-
sion factor is used to correct the observed data and it can be calculated from a matrix of between-session ratios or 
estimated using a maximum likelihood approach. Corrected values are obtained by dividing the observed values 
by the session factor. Finally, the gene expression ratio was calculated by dividing the N0 of the target gene by the 
N0 of the geometric mean of the three reference genes.
Genes UXT, RPS9 and GPAM were used as reference genes and those genes were validated by using the 
BestKeeper® tool described by Pfaffl et al.36 for determination of housekeeping stable genes. As BestKeeper© 
Software is limited to 100 data form the same gene at the same time, we used the formulae described in the paper 
to calculate the stability of the genes.
Univariate statistical analysis. Statistical analyses were performed using the IBM SPSS Statistics software 
package for windows (SPSS Inc., Chicago, USA). Test T was used to determine significant differences between 
groups. The nonparametric Mann–Whitney U test was used when data was no normally distributed. A one-way 
ANOVA approach was applied for comparisons of more than two groups. Normal distribution was tested using 
Kolmogórov-Smirnov and Levene to assess the equality of variances.
Multivariate statistical analysis. Multivariate statistical analyses were carried out using SIMCA-P + 12.0 
(Umetrics AB, Sweden). Firstly, gene expression data of nine genes measured in one hundred and ninety MSC 
samples from rbST-treated and control animals (IGF1R, CCND1, TNF, IL1β, SIRT2, EEFG1, MFEG8, LTF, 
TDP52L2) were logarithmically transformed and scaled according to the Pareto method. The other six target 
genes (IGF-1R, IGFBP3, IGFBP5, COL3A1, ESR2, CTNNAL1) were not included in multivariate statistical 
analyses because their expression was not detected or it was only detected in some samples. Principal compo-
nent analysis (PCA) was applied for a non-supervised visualization of the transcriptomic profiles and to detect 
extreme observations/samples in the MSCs dataset. Outliers were selected from the PCA using Hotelling’s T2 and 
distance-to-model in X space tools. Accordingly, extreme samples were removed from the data matrix before any 
further processing; MSCs samples with missing values in their transcriptomic profile (applied criteria for inclu-
sion: 0% missing observations) were also excluded. A supervised method, i.e. orthogonal projections to latent 
structures discriminant analysis (OPLS-DA), was secondly used adding information on class membership of the 
samples coded as Y variable (control samples or rbST samples). The quality of the OPLS-DA model was assessed 
by analysis of variance testing of cross-validated predictive residuals (CV-ANOVA), and its R2 and Q2 values. 
Lastly, to determine the variables (genes) more affected by rbST administration, and hence more appropriated to 
discriminate treated animals, the S-plot of the OPLS-DA model was used.
Gene symbol Gene name






IGF1 Insulin like growth factor 1 NM_001077828.1 bt03252281_m1 65
IGF1-R Insulin like growth factor 1 receptor NM_001244612.1 bt03649217_m1 70
IGFBP3 Insulin like growth factor binding protein 3 NM_174556.1 bt03223809_m1 77
IGFBP5 Insulin like growth factor binding protein 5 NM_001105327.2 bt03258785-g1 62
IL1β Interleukin 1 beta NM_174093.1 bt03212745_m1 129
TNF Tumor necrosis factor NM_173966.3 bt03259156_m1 69
LTF Lactotransferrin NM_180998.2 bt03217382_m1 95
COL3A1 Collagen type III alpha 1 chain NM_001076831.1 bt03249914_m1 88
TPD52L2 Tumor protein D52 like 2 NM_001034615.2 bt03227133_m1 78
ESR2 Estrogen receptor 2 NM_174051.3 bt03259198_m1 73
CTNNAL1 Catenin alpha like 1 NM_001191534.1 bt04308229_m1 76
SIRT2 Sirtuin 2 NM_001113531.1 bt03258971_m1 59
CCND1 Cyclin D1 NM_001046273.2 bt03235030_m1 72
MFGE8 Milk fat globule-EGF factor 8 protein NM_176610.1 bt03216856_m1 88
EEF1G Eukaryotic translation elongation factor 1 gamma NM_001040487.2 bt03229629_g1 74
Reference genes
UXT Ubiquitously expressed prefoldin like chaperone NM_001037471.2 bt03229278_m1 89
RPS9 Ribosomal protein S9 NM_001101152.2 bt03272016_m1 65
GPAM Glycerol-3-phosphate acyltransferase, mitochondrial NM_001012282.1 bt03210379_m1 97
Table 1. List of genes selected to evaluate their expression in somatic cells. *Primers and probes used in 
this study are proprietary information of ThermoFisher Scientific. Information about amplicon size, context 
sequence and assay location can be consulted by introducing the assay ID on www.thermofisher.com webpage.
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Results and Discussion
Effect of rbST on milk yield. Table 2 shows a summary of milk yield for the rbST and control groups 
expressed as mean and standard deviation of milk production (Kg per day) at each treatment cycle, as well as 
production difference between both groups (% of extra milk produced by rbST group in comparison to control 
animals). From cycle 0 to cycle 3, milk production seems to increase in both groups, possibly indicating that 
animals had not yet reached their peak of lactation. Although the first dose of rbST was administered around 2 
months post-partum, as recommended by the manufacturer, it is important to note that this recommendation is 
based on mathematical models that locate the milk production peak at 60–90 days postpartum. However, these 
models are only theoretical approaches and days in milk (DIM) at the milk peak have a wide variation between 
herds and cows, being conditioned, amongst other factors, by welfare and feeding37. From cycle 4 to the end of the 
study, a decrease in milk production of control cows could be glimpsed while the rbST-treated animals seemed to 
maintain their production relatively constant on 30–35 kg average of milk per day, showing an obvious decreasing 
tendency only when the hormonal treatment was stopped (cycles 14, 15 and 16). At this point, the production 
differences observed between groups returned to levels very close to those observed at cycle 0. It is remarkable the 
fact that milk production was significantly higher in the rbST group than in the control during the whole study, 
except during cycle 6 when these animals were producing only 5% more than control subjects (Table 2). On the 
basis of the biweekly administration pattern of rbST recommended by the manufacturer, on day 70 the group of 
treated animals should have received a new dose of recombinant growth hormone. However, that dose was not 
applied so as to be able to evaluate if the rbST group could recover the pre-dose transcriptional profile after 28 
days without hormonal administration (Fig. 1). Possibly due to this lack of hormone, the statistically significant 
differences existing in milk production between the two groups disappeared, highlighting the effects of rbST on 
milk production rates (Table 2). At day 84, rbST was administered again and the significant differences in milk 
production between the two groups reappeared (24%). A maximum difference of 43% more milk in treated ani-
mals with respect to control cows was observed at cycle 12, both related to a maintained production due to rbST 
and a natural decreasing pattern in control females. Curiously, these significant differences were maintained until 
the end of the study, even almost two months after the last dose (12th dose, day 168) was administered (Table 2).
RNA isolation from bovine somatic cells. MSCs are easy-to-collect source of RNA for gene expression 
studies, as these cells can be isolated from raw milk following a very simple protocol. Besides, sample collection is 
cheap and non-invasive, since milk can be collected in the milking room without direct contact with the animal 
and therefore without causing stress to it which could alter the results obtained. In this study, the rbST treatment 
had no significant effect (P = 0.099) on the quantity of RNA isolated from MSCs, with a mean concentration of 
120.69 ± 68.31 µg mL−1 in samples from the rbST group and 132.36 ± 68.86 µg mL−1 in samples from the control 
group. The mean A260/280 ratio value was 1.766 ± 0.095. It is possible that a purification step with spin columns 
increased the A260/280 ratio and therefore the purity of the RNA samples. Although the inclusion of this step 
increases the sample price in routine analysis, it allows obtaining samples with higher purity. The mean RIN 
value observed for the samples analysed was 6.88 ± 0.82 Some factors could affect to the integrity of the samples. 
Milk yield (mean kg/day)
Days of 
study
Months in lactation 
(mean)
rbST (N = 6) Control (N = 3)
Production 
difference (%) rbST Control
Cycle 0 40.41 ± 6.21** 33.94 ± 12.43 19.28 ± 4.96 −18 to 0 2.0 2.5
Cycle 1 40.53 ± 6.68** 35.43 ± 9.85 14.97 ± 7.14 1 to14 2.5 3.0
Cycle 2 42.22 ± 6.25** 37.38 ± 8.87 13.05 ± 4.99 15 to 28 3.0 3.5
Cycle 3 42.31 ± 5.84** 37.87 ± 8.01 11.80 ± 4.58 29 to 42 3.5 4.0
Cycle 4 38.49 ± 8.18* 35.00 ± 7.08 10.15 ± 6.45 43 to 57 4.0 4.5
Cycle 5 37.21 ± 8.27* 34.67 ± 6.65 7.38 ± 4.51 58 to 70 4.5 5.0
Cycle 6 35.00 ± 6.89 33.24 ± 4.73 5.44 ± 6.64 71 to 84 5.0 5.5
Cycle 7 35.09 ± 9.20*** 28.43 ± 6.78 24.06 ± 8.99 85 to 98 5.5 6.0
Cycle 8 32.88 ± 7.92*** 27.46 ± 4.59 19.89 ± 7.11 99 to 112 6.0 6.5
Cycle 9 36.13 ± 7.39*** 29.18 ± 3.30 24.10 ± 6.04 113 to 127 6.5 7.0
Cycle 10 37.14 ± 6.29*** 28.39 ± 2.83 30.99 ± 4.11 128 to 140 7.0 7.5
Cycle 11 34.70 ± 6.07*** 27.42 ± 2.47 26.70 ± 7.35 141 to 154 7.5 8.0
Cycle 12 32.06 ± 5.50*** 22.60 ± 6.86 43.26 ± 15.02 155 to 168 8.0 8.5
Cycle 13 32.31 ± 7.17*** 24.75 ± 4.96 30.52 ± 10.56 169 to 182 8.5 9.0
Cycle 14 28.38 ± 6.55** 24.10 ± 5.39 18.22 ± 5.93 183 to 196 9.5 10.0
Cycle 15 29.82 ± 4.90*** 25.91 ± 3.80 15.67 ± 9.77 196 to 209 10 10.5
Cycle 16 28.37 ± 4.85*** 24.12 ± 5.50 13.03 ± 6.94 209 to 222 10.5 11
Table 2. Milk yield in treated (N = 6) and control group (N = 3) along the study. Data was divided in cycles 
based in rbST administration cycles of two weeks. The mean milk production of each cycle was calculated. The 
day 0 of study is the day of the first rbST dose administration. Cycle 6, 14, 15, 16 has no administration of rbST 
and the last day of the cycle correspond with the last sampling for transcriptomic assays. The test-T was used to 
compare the milk yield in each cycle between treated and control group.
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The samples used in this study were bovine somatic cells isolated from milk. Milk is characterized by a complex 
microbiota and RNases derived from that microbiota could be responsible of a lower RNA integrity. In addition, 
some of somatic cells present in milk could be partially degraded. These facts were also observed in a study that 
used bovine vaginal smear for transcriptomics studies with the aim to find biomarkers to trace the misuse of 
anabolic agents38. Also, the process of milking, milk collection and transportation to the lab could, despite being 
carried out with the as swiftly as possible, affect to the RNA integrity.
Effect of rbST on somatotropic axis genes. A set of 18 genes (Table 1) were selected for designing the 
OpenArray® plates used in this study. This selection was based on the potential of these genes to obtain a char-
acteristic rbST transcriptomic signature that could be used as a standard to control the ab(use) of rbST in dairy 
cattle. Previous gene expression studies with rbST were designed as single-dose and single sampling studies in 
post-mortem mammary tissue27 or multi-dose (five doses) studies with blood and muscle sampling in vivo31. 
Those methods are considered invasive, relatively expensive and therefore impractical for control purposes on 
dairy farms. In the case of somatotropin, the control must be performed in vivo, since the ultimate goal is to avoid 
the entry of rbST-milk into the dairy market.
In this study, the expression of IGF-1 was only detected at all the sample points in one cow (cow 7) treated 
with rbST and it was not detectable in the MSCs of control group. The fact that it was only possible to detect the 
IGF-1 target at all the sample points in one cow may indicate the existence of different local mammary gland 
responses to exogenous rbST among individuals. Most IGF-1 molecules found in the circulation are bound with 
high affinity to one or more of the six known IGF-1 binding proteins (IGFBP-1–6) that modulate the bioavailabil-
ity of IGF-1 in target tissues39. Previous studies have observed that rbST strongly influences the upregulation of 
IGFBP-5 in skeletal muscle of cattle31 and downregulates IGFBP-3 in mammary tissue32. However, in this study, 
transcripts of neither IGFBP-3 nor IGFBP-5 were detected at any time point. This result could be due to MSCs 
being composed mainly of leukocytes40 in which the repressive effect of IGFBP may not be as important as in 
mammary tissue. Therefore, both IGF-1 and IGF-1 binding proteins are discarded as potential markers in somatic 
cells in this study.
Another key component of the somatotropic axis is the IGF-1 receptor (IGF-1R) which is the primary sig-
nalling receptor for IGF-1 that mediates most of its biological effects. On day 1 the rbST group (0.348 ± 0.131) 
had a significantly (P < 0.001) higher relative abundance of IGF-1R than the control group (0.0898 ± 0.0486). 
Different studies that evaluated the concentration of rbST in blood after administration observed that the higher 
concentrations of this recombinant hormone were found after rbST administration14,15. Therefore, the significant 
differences observed in treated group could be due as a response to the IGF-1 synthesized as response the higher 
concentrations of rbST in treated cows after first dose administration. In Fig. 2, it can be observed that the relative 
abundance of IGF-1R for the two first cycles of rbST administration was also significantly higher in the rbST 
group than in the control group in many sample points. Curiously, on day 84 of the study, the relative abundance 
of IGF-1R was similar in the rbST group (0.070 ± 0.057) and in the control group (0.110 ± 0.030). This day coin-
cided with the sixth administration of rbST, and between this dose and the fifth dose there was a gap of 28 days 
instead of 14 days. Therefore, it is possible that the rbST group recovered the physiological level of IGF-1R after 
several days without rbST, showing even withdrawal effects of down-regulation on IGF-1R transcription. These 
results indicate that IGF-1R is a possible good candidate for inclusion in a panel of genes to detect the use of rbST 
in dairy farms. Although other authors did not find a significant effect of rbST on IGF-1R levels in skeletal mus-
cle31, in this study a clear response was observed in the levels of this receptor transcript in MSCs. In this sense, 
leukocytes, neutrophils and monocytes can produce growth hormone and IGF-1 and express their receptors that 
indicate that IGF-1/IGF-1R signalling pathways might exert regulatory functions on the immune system includ-
ing immune cell proliferation41,42. The difference between the two studies could be due to the different matrices 
used. MSCs could possibly respond better to the higher levels of circulating IGF-1 and increase the number of 
receptors for this molecule in their membrane
Figure 2. Relative abundance of IGF-1R and CCND-1 in the first and second cycles of rbST administration 
in control group (N = 3) and treated group (N = 6). The nonparametric Mann–Whitney U test was used 
to compare the milk yield in each cycle between treated and control group. Asterisks represent statistically 
significant differences between treated group and both control group. *(p < 0.05), **(p < 0.01), ***(p < 0.001).
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Effect of rbST on immune system-related genes. Tumour necrosis factor (TNF) and interleukin-1β 
(IL-1β) are two cytokines closely related to the immune system43. Due presumably to their relationship, it was 
possible to identify similar trends in the relative abundance of TNF and IL-1β transcripts throughout the study. 
The rbST administration provoked a significant increase in the relative abundance of TNF and IL-1β transcripts. 
It is worth mentioning that on days 9, 23 and 35, the relative abundances of TNF and IL-1β were significantly 
higher in the rbST group in comparison to the control group (Fig. 3). These days correspond to the second week 
of rbST cycles, approximately 7–9 days after injections of Lactotropina®. Therefore, it is possible that the tran-
scriptomic changes caused by rbST in these two cytokines are more evident in the second week of an rbST cycle. 
Curiously enough, on day 84 (28 days after the 5th rbST administration), there was no significant differences 
between groups (Fig. 3). In this context, other previous studies have used powerful transcriptomic technologies 
to detect the use of anabolic agents in cattle26,38. These studies also observed an increased transcription of IL-1β, 
one of them significantly26, and this is very interesting because the referred study used blood cells which compo-
sition is very similar to that of MSCs, as they have a high proportion of white blood cells. However, the previously 
mentioned studies did not find an effect of anabolic agents on TNF, while the present research found a strong 
influence of rbST administration on the relative abundance of TNF. With this regard, it has been reported that the 
exogenous administration of rbST during lactation can enhance the immune response in cows44. Actually, milk 
somatic cell counts increased earlier and faster in cows suffering from coliforme mastitis when rbST was admin-
istered45. Growth hormone and its recombinant version show the ability to modulate the inflammatory reaction 
and neutrophil defense of the bovine lactating mammary gland in health and diseased cows45. This could explain 
the upregulation of TNF and IL-1β in rbST treated cows.
In screening studies by using transcriptomics it is very difficult to find a specific gene that could be used as 
very trusty gene. It should be noted that both IL-1β and TNF can be upregulated in other processes as sub-clinical 
mastitis46,47. Different studies carried out in the United States have observed that large farms are more likely 
to adopt rbST, suggesting not only a potential farm-size component of rbST use and profitability but also an 
operator (age and education) component48,49. Recombinant somatotropin has been frequently reported as a 
management-intensive technology, associated with the use of other productivity-oriented technologies and man-
agement practices that are characteristic of larger farms, being less frequent among grazers49,50. In this sense, 
subclinical mastitis causes a reduction in milk production in affected cows51. Therefore, it should be interesting to 
combine the data of transcriptomic assays with the milk production data. Also it could be accompanied by a milk 
microbiological assay of suspected cows to detect the principal pathogens associated with subclinical mastitis. But 
what really increases the potential for discrimination is the inclusion of more genes in the panel.
Effect of rbST on cell cycle, proliferation, differentiation and adhesion. It is know that rbST 
increases milk synthesis by increasing the turnover (proliferation/apoptosis) and activity of mammary epithelial 
cells, indicating that rbST influences metabolic pathways that regulate cell turnover/cycle and metabolism52. The 
Figure 3. Relative abundance of CCND1, IGF-1R, IL1β and TNF transcription of rbST treated group (N = 6) 
and control group (N = 3) on days -10, 1, 9, 23, 35, 84. Samples for a single day of outside control cows (N = 3) 
were added. A one-way ANOVA approach was applied for comparisons of more than two groups. Asterisks 
represent statistically significant differences between treated group and both control group. *(p < 0.05), 
**(p < 0.01), *** (p < 0.001).
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cell cycle is controlled by cyclins and cyclin-dependent kinases. Of those, cyclin D (endoded by the CCND1 gene) 
coordinates cell cycle progression through extracellular stimulation (e.g., growth factor, nutrient availability) and 
drives G1 to S phase progression resulting in cell mitosis. However, most adult cells are maintained in a quies-
cent state known as G0 phase, a resting state, and they can re-enter the cell cycle in G1 phase under appropriate 
mitogenic stimuli53. In this study, it was observed that rbST treatment strongly influences CCND1 transcription. 
Before the first dose of rbST, there were no significant differences between the control and rbST groups (Fig. 3). 
However, after the first dose, it was possible to observe significant differences between the two groups at different 
sample points. The relative abundance of CCND1 was significantly higher in the rbST group than in the control 
group in the two first cycles of rbST treatment (Fig. 2). This effect seems to be particularly evident 9 days after 
rbST administration, similarly to TNF and IL-1β transcripts. Thus, on days 9, 23 and 35 of the study, the relative 
abundance of CCND1 was significantly higher in the rbST group than in the control group (Fig. 3). Finally, on day 
84 (28 days after the 5th rbST administration), there were no significant differences between groups (Fig. 3) as in 
the case of the cytokines. Also, on the last day (219) of sampling (51 days after the last rbST doses), there were no 
significant differences (P > 0.05) between the rbST group (0.433 ± 0.141) and the control group (0.430 ± 0.178). 
Therefore, the exogenous administration of rbST causes an overexpression of CCND1. This can result in the acti-
vation of cell in G0 phase, and in the particular case of mammary tissue, an increase in milk production through 
increasing the number of alveolar cells of mammary gland54.
Other genes related to cell cycle are tumour protein D52-like 2 (TPD52L2) and sirtuin 2 (SIRT2). In a manner 
similar to that observed for CCND1, TNF and IL-1β, it was possible to find a significantly higher (P < 0.001) rel-
ative abundance of SIRT2 transcripts in the rbST group (1.517 ± 0.199) than in the control group (0.506 ± 0.250) 
on day 23 of the study, but in this case just during the second cycle of rbST administration (Fig. 4). The increased 
levels of CCND1 and SIRT2 transcripts after the second administration of Lactotropina® in the treated group 
could be the result of an effect of exogenous rbST on cell cycle. The circulation of this peptide hormone in the 
organism would result in the activation of the cell cycle in the target cells. However, in the other rbST cycles, the 
relationship between dose administration and changes in the relative abundance of SIRT2 transcripts was not 
as evident as in the second dose. In addition to the foregoing, it is remarkable that the treated group presented 
a significantly higher relative abundance of TPD52L2 transcripts (P < 0.05) during 4 days after the first rbST 
administration. Another component implicated in cell metabolism by its relevant role in translation is eukaryotic 
elongation factor 1 gamma (EEF1G).
In this study, the relative abundance of EEF1G transcripts did not follow an obvious tendency related to rbST 
administration. However, on days 17 and 30 (3 and 2 days after the second and third rbST doses, respectively), 
the relative abundance of EEF1G transcripts was significantly higher in the rbST group. A previous study27 con-
cluded that rbST treatment increases the levels of EEF1G transcripts in mammary tissue but it only used one 
sample point 6 days after somatotropin administration. Therefore, it is not possible to directly compare those 
results with the results obtained in this study, in which 36 sample points were used for transcriptomic assays over 
the course of 8 months. Another gene included in this study is milk fat globule-EGF factor 8 protein (MFGE8). 
In Fig. 4, it is possible to observe that the relative abundance of MFGE8 in the rbST group had great variability 
between sampling days. In particular, McCoard et al.27 observed that 6 days after rbST administration, the relative 
abundance of MFGE8 in bovine mammary tissue was higher. However, as mentioned before, that study included 
only one data point after a single rbST dose. The present long-term multi-dose experiment has demonstrated that 
transcription patterns in bovine animals treated with rbST have great variability over time. For example, data 
obtained for CCND1 showed that the effect of rbST on the transcription of some genes increases with the num-
ber of doses. Although it is possible that rbST influences the transcription of the MFGE8 gene, obtained results 
showed both up- and down-regulation. Therefore, MFGE8 cannot be suggested as an ideal candidate for tracing 
rbST (ab)use in cattle, as it was not possible to observe a clear tendency in its transcription. Another gene related 
Figure 4. Evolution of the relative abundance of some target genes during all the sample points of the study in 
rbST treated group (N = 6) and control group (N = 3).
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to cell adherence evaluated in this study is catenin alpha-like 1 (CTNNAL1). However, it was not possible to find 
significant differences in its transcription as a result of rbST administration.
other genes. Lactoferrin (LTF) is an iron-binding glycoprotein belonging to the transferrin family55. Figure 4 
shows the evolution of LTF gene relative abundances at all sample points evaluated in this study. Although upreg-
ulation of LTF was observed in previous studies with anabolic substances in cattle38, it was not possible to estab-
lish a clear tendency for LTF in relation to rbST treatment. For example, on days 9 and 53, the relative abundance 
of LTF considerable lower in rbST-treated animals. However, on day 91, the relative abundance was considerable 
higher in that group. It is necessary to discuss the results obtained for the collagen type III α 1 (COL3A1) gene. 
A previous study concluded that treatments with rbST in dairy cattle cause upregulation of the COL3A1 gene in 
mammary tissue 6 days after rbST administration27. However, in the present work it was not possible to detect 
transcripts of the COL3A1 gene. Also ESR2 transcription was not detected in this study.
A panel of genes to monitor rbst (ab)use in dairy cattle. The final aim of this work was to propose 
a routine panel of genes whose combined transcription pattern would allow the development of a screening 
method to control the misuse of rbST in dairy farms via MSCs. Unlike other previous studies27,31,32, this work 
analysed the transcription patterns of rbST-related genes in a 8-month real-conditions experiment including 12 
cycles of rbST administration and control animals. This approach permitted more accurate data to be obtained in 
order to differentiate between rbST-treated cows and control cows.
Multivariate statistical analysis was run to elucidate modifications in MSCs transcription patterns as a con-
sequence of rbST administration. For this purpose, only the transcript of the nine genes that were successfully 
measured over the whole experiment (IGF1R, CCND1, TNF, IL1β, SIRT2, EEFG1, MFEG8, LTF, TDP52L2) were 
used, excluding those genes that only expressed in very few cases/samples. The main goal of PCA analysis is to 
identify global patterns in data, detecting the correlation between different variables, i.e. in this particular case, 
transcriptions of different genes. Projection of the samples into the new multidimensional space of the principal 
components (PCs) would potentially allow a differentiation between rbST and control groups, highlighting also 
those genes with a greater ability as biomarkers of the treatment. In the score plot of the PCA analysis shown in 
Fig. 5, a grouping tendency could be glimpsed in the two groups of MSC samples, with rbST-treated animals iden-
tified as red circles and control animals as black boxes, and labelled according to the experimental day. Various 
samples of rbST group appeared mixed with controls on the left side of the plot but, curiously enough, the major-
ity of them correspond to a day of somatotropin administration (days 14, 28, 57 or 84) or to the first 2–3 days 
after a dose (days 2, 3, 17, 44 or 115), in which an evident transcriptomic disturbance was not detected. On the 
contrary, very few control animals could be classified as treated cows on the PCA, and their situation is explained 
by extreme values in particular poorly discriminative genes such as LTF, MFGE8 or SIRT2.
The transcriptomic profiles were also subjected to an OPLS-DA, from which potential discriminative genes 
were also pointed out. In Fig. 6a, the visual representation of the multivariate model is shown, with MSC sam-
ples from control animals plotted as black squares and samples from rbST group as red circles. In a similar 
way to PCA, several rbST samples are projected among control samples on the left side of the ellipse. However, 
these samples were collected when the transcriptomic disturbance caused by rbST had disappeared (or had not 
appeared yet), so strictly, they could be classified as controls in that specific moment. Conversely, very few control 
samples were misclassified as rbST. When no test set is available as is this case here, the cross-validation method 
is the main strategy to assess the quality of a model. Results of the cross-validation procedure are summarized 
by the value of different quality parameters. In this study, the OPLS multivariate model showed the following 
Figure 5. PCA plot built using full transcriptomic profiles of milk somatic cells (MSCs), in which a 
discrimination between cows treated with rbST (N = 6, red circles) and control animals (N = 3; black boxes) 
can be glimpsed. MSC samples are labelled according to day of experiment, being day 0 the day of the first rbST 
dose in treated animals.
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characteristics: R2(X) = 0.6, R2(Y) = 0.4 and Q2 = 0.3. The model explains 60% of the variation in x-space and 40% 
of the variation in y-space, and goodness of prediction is 30%. These values indicate a relatively good descrip-
tion of the data by the model and average predictability34. The p-value calculated from the CV-ANOVA was 
3.01 × 10−7, suggesting the existence of significant differences between the two classes of the model. The fact 
that this model was built with a panel of genes with different discriminating ability should not be ignored, as it 
affects the discriminating power of the OPLS. Besides, those experimental days with very little or no rbST-effect 
on their transcripts are definitely biasing the model since in the practice they belong to one group but act as the 
other. In future multivariate screening models, a panel of selected highly discriminative genes must be used, and 
preferably, “known” and “unknown” samples to be projected in the multivariate model will belong to similar pop-
ulations (age, breed, etc.) and lactation moments, in an attempt to overcome inter-individual animal variability35. 
In this kind of approaches, it is also important that the predictive population is larger than the predicted samples. 
Finally, the reasons for discrimination on the OPLS-DA were investigated in the corresponding S-plot (Fig. 6b), 
which revealed the contribution of each variable (gene transcription) to the separation of the two sample classes. 
As commented in previous sections, the most discriminant transcription in MSC was found in CCND1, IGF-1R, 
TNF and IL-1β genes. It appears clear that rbST treatments trigger an upregulation of those genes and their usein 
future monitoring panels is a promising option for routine control in dairy.
As in a routine control to detect illicit use of rbST with this gene panel, there would be no information about 
when cows have been treated (in others words, it is a blind assay), ideally every day during lactation should be 
sampled/controlled. However, from a practical point of view, this suggestion sounds a bit unrealistic. What it is 
proposed is a random collection of milk once per week, alternating week days. As somatotropin is administered 
on a regular basis throughout lactation (starting 80–100 days postpartum, bi-weekly), in all lactating cows of the 
farm, with a good sampling plan, at some point rbST should be detected in the farm. The transcriptomic data 
obtained from the samples collected have to be compared with a transcriptomic dataset from a control popula-
tion. Those samples that presented higher values of genes proposed in this paper should be considered as suspi-
cious. The second step should be investigating the particular situation of each “positive” cow (mastitis, pregnancy, 
etc.), and, if required, continue to confirmatory analysis. It is important to highlight also the high-throughput 
capacities of this real time PCR approach, making feasible the sampling plan.
Figure 6. OPLS-DA scatter plot (a) constructed using trasncriptomic profiles from milk somatic cells, showing 
a discrimination between control (N = 3; black circles) and rbST (N = 6; red dots) animals, labelled according 
to the experimental day (being day 0 the day of 1st dose in rbST group). S-plot (b) associated to the OPLS 
discriminant analysis, highlighting the genes more affected by rbST on the upper right corner of the plot, and 
hence with a higher discriminative power.
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Conclusion
This multi-dose longitudinal study with 12 rbST treatments and 36 sample points in real dairy farm conditions 
has allowed establishing a trustworthy transcription profile for both rbST-treated and controlling groups. These 
data in combination with multivariate statistical analysis showed that the transcription of CCND1, IGF-1R, IL-1β 
and TNF genes in MSC could be used as promising markers in a panel designed for screening of rbST misuse on 
dairy farms. Even though the implementation of this new approach is very challenging and sophisticated for real 
routine testing, it can be considered of valuable scientific interest and a starter point for future studies on the field.
Data Availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
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